TrialJournal of psychopharmacology (Oxford, England)2025

Six weeks open-label oral ketamine for patients with treatment-resistant depression, post-traumatic stress disorder, or obsessive-compulsive disorder.

Ben Beaglehole et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.